Metastatic prostate cancer means prostate cancer cells have spread from the prostate to a distant site in the body. In TNM staging this is M1 disease. The most common clinically important patterns involve distant lymph nodes and bone, while some patients develop spread to organs such as the liver or lungs. A metastasis still consists of prostate-cancer cells—so a prostate cancer deposit in bone is metastatic prostate cancer in bone, not primary bone cancer. Once distant spread is established, treatment is built around systemic cancer control, while radiation, bone-directed care and other local treatments can be added for selected disease sites or symptoms.
Metastatic prostate cancer is classified by where the distant cancer is found: M1a for non-regional lymph nodes, M1b for bone and M1c for other distant sites. It is also classified by how the cancer responds to androgen suppression: metastatic hormone-sensitive disease still responds to lowering or blocking androgen signaling, while metastatic castration-resistant disease progresses despite castrate testosterone levels. These are different clinical dimensions and both affect treatment.
01How Does Prostate Cancer Spread From the Prostate?
Metastasis is a multistep biological process
A prostate-cancer cell does not become metastatic simply because a tumor is large.
To establish a distant metastasis, cancer cells must acquire the ability to:
- invade surrounding tissue;
- enter lymphatic channels or blood vessels;
- survive transport away from the prostate;
- leave the circulation at another location;
- adapt to a new tissue environment;
- and grow into a metastatic deposit.
Can prostate cancer spread through lymphatic channels?
Yes.
Cancer cells can move through lymphatic drainage pathways from the prostate into pelvic lymph nodes.
Regional pelvic lymph nodes are classified as N1, not M1.
If cancer reaches non-regional lymph nodes, the disease becomes:
M1a.
This distinction is important because prostate cancer staging separates regional nodal spread from distant metastasis.
Can prostate cancer spread through the bloodstream?
Yes.
Hematogenous spread allows cancer cells to reach distant organs and bone.
Bone has a particularly important relationship with advanced prostate cancer because prostate-cancer cells can interact with:
- bone marrow;
- osteoblasts;
- osteoclasts;
- vascular tissue;
- and signaling molecules in the skeletal microenvironment.
Why does prostate cancer commonly spread to bone?
The exact biology is complex.
Factors include:
- patterns of venous and marrow circulation;
- adhesion between cancer cells and bone-marrow tissue;
- growth signals within bone;
- and tumor–bone interactions that can support metastatic growth.
Prostate bone metastases often stimulate abnormal bone formation as well as bone breakdown, producing the classically osteoblastic or sclerotic appearance seen on some imaging studies.
Is a prostate cancer bone metastasis actually bone cancer?
No.
This distinction is fundamental.
A bone metastasis contains prostate-cancer cells that originated in the prostate.
It is therefore treated according to prostate-cancer biology.
The same principle applies if prostate cancer spreads to:
- a distant lymph node;
- the liver;
- the lung;
- or another organ.
Can cancer spread directly into nearby structures without being metastatic?
Yes.
Direct extension through the prostate boundary is local progression rather than distant metastasis.
Examples include:
- extraprostatic extension;
- seminal-vesicle invasion;
- and invasion of nearby pelvic structures.
Those patterns fall within the advanced prostate cancer spectrum but may remain M0.
Metastasis does not mean the new tissue becomes a different cancer. When prostate adenocarcinoma spreads to bone or liver, pathology and treatment still identify it as prostate cancer because the malignant cells originated in the prostate.
02Where Does Metastatic Prostate Cancer Commonly Spread?
Bone is one of the most characteristic metastatic sites
Skeletal metastases are common in advanced prostate cancer.
Frequently involved regions include:
- spine;
- pelvis;
- ribs;
- proximal long bones;
- and other parts of the axial skeleton.
Bone involvement is classified:
M1b.
Why do prostate cancer bone metastases often look sclerotic?
Prostate cancer commonly stimulates abnormal osteoblastic activity.
This can produce areas of increased bone formation and density on CT or X-ray.
However, metastatic bone biology is not purely bone-forming.
Tumor involvement can simultaneously:
- disrupt normal bone remodeling;
- weaken bone structure;
- cause pain;
- increase fracture risk;
- and contribute to spinal instability or cord compression.
Do bone metastases always cause pain?
No.
Some skeletal metastases are found only on imaging.
When pain occurs it is often:
- persistent;
- focal;
- progressive;
- or worse with movement when structural bone damage is present.
But ordinary back, hip or joint pain is extremely common and should not automatically be interpreted as metastatic prostate cancer.
Can prostate cancer spread to lymph nodes?
Yes.
The important question is which lymph nodes.
Regional pelvic lymph nodes belong to the N category.
Distant non-regional lymph nodes are:
M1a.
Can prostate cancer spread to the liver?
Yes.
Liver metastases occur in a subset of men with advanced disease and are generally classified within M1c.
Visceral metastases often indicate more biologically aggressive disease and can influence systemic-treatment planning.
Can prostate cancer spread to the lungs?
Yes.
Lung metastases can occur, either alone or with other metastatic sites.
They also fall within:
M1c.
Can prostate cancer spread to the brain?
It can, but brain metastases are far less common than bone or nodal spread.
New neurological symptoms in a patient with advanced cancer require clinical evaluation, but most headaches or neurological symptoms are not caused by prostate-cancer brain metastasis.
Can one patient have several metastatic categories at the same time?
Yes.
A patient may have:
- distant lymph-node disease;
- bone metastases;
- and visceral metastases
at the same time.
The pattern and burden of metastases can affect:
- prognosis;
- treatment selection;
- need for symptom-directed radiation;
- and bone-health management.
What is low-volume versus high-volume metastatic disease?
Several clinical trials classify metastatic burden using criteria such as the CHAARTED definition.
Under that research definition, high-volume disease generally means:
- visceral metastases;
- or at least four bone metastases, with at least one outside the vertebral bodies or pelvis.
Disease not meeting those criteria is considered low volume for that specific framework.
This classification matters because evidence for some treatments—particularly radiation to the primary prostate in newly diagnosed metastatic disease—differs by metastatic burden.
What is de novo metastatic prostate cancer?
De novo metastatic disease means distant metastases are already present when prostate cancer is first diagnosed.
This differs from metachronous metastatic disease, where metastases appear later after an earlier localized diagnosis or treatment.
Those disease histories can influence treatment decisions and prognosis.
Bone metastasis deserves separate attention because skeletal complications can become clinically important. The next guide focuses specifically on prostate-cancer bone metastases, including pain, fractures, spinal cord compression, imaging and bone-directed treatment.
03How Are Metastases Detected, and What Symptoms Can They Cause?
Metastatic disease may be found before symptoms appear
Some men are diagnosed with metastatic prostate cancer because staging imaging reveals distant disease even though they feel well.
Others are investigated because of:
- very high or rising PSA;
- high Grade Group;
- advanced local stage;
- bone pain;
- weight loss;
- fatigue;
- or symptoms related to a specific metastatic site.
Can PSA diagnose metastatic prostate cancer?
No.
PSA can increase concern for metastatic disease, but it cannot show:
- whether metastases are present;
- where they are;
- how many are present;
- or which organ is involved.
Very advanced prostate cancer can sometimes produce surprisingly modest PSA values, particularly when tumor biology has changed, so imaging and pathology context remain important.
How is PSMA PET/CT used?
PSMA PET/CT uses a radiotracer that binds to prostate-specific membrane antigen expressed by many prostate-cancer cells.
It can identify:
- regional lymph-node disease;
- distant nodal metastases;
- bone metastases;
- and some visceral metastases.
Current European guidance recognizes PSMA PET/CT as more sensitive than conventional CT and bone scan for many nodal and skeletal metastases.
Does a PSMA-positive spot always mean prostate cancer?
No.
PSMA uptake is not perfectly cancer-specific.
Interpretation requires:
- anatomical location;
- CT findings;
- overall scan pattern;
- known prostate-cancer history;
- and expert nuclear-medicine interpretation.
Benign conditions and some non-prostate tumors can also show PSMA uptake.
What is a bone scan?
A conventional radionuclide bone scan detects increased bone turnover rather than directly imaging prostate-cancer cells.
It has historically been used for skeletal staging.
Areas of increased activity can also occur from:
- arthritis;
- fracture;
- infection;
- or other benign bone processes.
What does CT contribute?
CT can assess:
- lymph-node enlargement;
- visceral metastases;
- bone sclerosis;
- urinary obstruction;
- and other structural consequences of advanced disease.
Small nodal metastases can be missed when nodes remain normal in size.
What does MRI contribute?
MRI is especially valuable when clinicians need high soft-tissue or marrow detail.
It can be used to evaluate:
- spinal metastases;
- bone marrow involvement;
- possible spinal cord compression;
- pelvic tumor extension;
- and selected focal neurological or musculoskeletal symptoms.
What symptoms can bone metastases cause?
Possible symptoms include:
- persistent focal bone pain;
- pain with movement;
- night pain;
- fracture;
- weakness from spinal involvement;
- or pain radiating from a compressed nerve root.
When can spinal metastases become an emergency?
New or rapidly worsening back pain with leg weakness, numbness, difficulty walking, saddle-area sensory change or new loss of bladder or bowel control requires urgent medical assessment. In a person with known or suspected cancer, these features can indicate metastatic spinal cord or cauda-equina compression. Immediate imaging and treatment may be needed to preserve neurological function.
Can lymph-node metastases cause symptoms?
Often they do not.
Bulky nodal disease can occasionally contribute to:
- leg swelling;
- ureteral obstruction;
- hydronephrosis;
- or pelvic discomfort.
Can metastatic disease cause anemia or fatigue?
Yes.
Advanced cancer can contribute to:
- anemia;
- fatigue;
- weight loss;
- reduced appetite;
- and declining physical function.
Treatment itself can also contribute, particularly androgen deprivation, chemotherapy and advanced illness.
Can metastatic disease exist with no symptoms?
Yes.
This is why symptoms alone cannot determine stage.
A patient with high-risk prostate cancer can have clinically important metastatic disease detected on imaging before pain or constitutional symptoms develop.
Symptoms do not measure metastatic burden reliably. A man with several small metastatic lesions may feel completely well, while one strategically located spinal lesion can cause major neurological symptoms. Anatomical site often matters as much as total lesion count.
04How Is Metastatic Prostate Cancer Treated?
Treatment begins by identifying hormone sensitivity
Most newly diagnosed metastatic prostate adenocarcinomas remain dependent on androgen-receptor signaling.
This disease state is called:
- metastatic hormone-sensitive prostate cancer;
- metastatic castration-sensitive prostate cancer;
- mHSPC;
- or mCSPC.
These terms refer to the same broad treatment-response state.
What is androgen-deprivation therapy?
Androgen-deprivation therapy, or ADT, reduces testosterone signaling that stimulates prostate-cancer growth.
It can be achieved with:
- medical suppression using GnRH agonists;
- medical suppression using GnRH antagonists;
- or surgical removal of the testicular source of androgen production through orchiectomy.
Is ADT alone enough for newly diagnosed metastatic prostate cancer?
For most fit men who can receive combination therapy, ADT alone is no longer the preferred routine approach.
Current EAU guidance recommends treatment intensification for appropriate M1 patients.
Depending on the individual clinical setting, ADT may be combined with an androgen-receptor pathway treatment such as:
- abiraterone plus prednisone;
- apalutamide;
- enzalutamide;
- darolutamide in selected settings;
- or another guideline-supported agent available in the relevant country.
When is docetaxel used?
Docetaxel chemotherapy can be used in selected fit men with metastatic hormone-sensitive disease.
Current EAU guidance emphasizes its use as part of an intensified combination rather than routine ADT-plus-docetaxel doublet therapy when effective androgen-receptor pathway treatment is available.
Suitability depends on:
- fitness;
- comorbidities;
- disease burden;
- previous therapy;
- and tolerance for chemotherapy toxicity.
What is triplet therapy?
Triplet treatment combines:
- ADT;
- docetaxel;
- and an androgen-receptor pathway agent such as darolutamide or abiraterone in evidence-supported regimens.
It is considered for selected patients rather than automatically given to every man with metastatic disease.
Can radiation to the prostate help when metastases are already present?
Yes, in a defined subgroup.
For men whose first presentation is metastatic hormone-sensitive prostate cancer with low-volume metastatic disease, current EAU guidance recommends adding prostate radiotherapy to systemic ADT-based treatment.
Randomized evidence has shown survival benefit in the low-volume subgroup, while the same survival benefit has not been demonstrated for unselected high-volume metastatic disease.
Does radiation to the prostate replace systemic treatment?
No.
Once M1 disease is present, systemic therapy remains central.
Radiation to the primary prostate is an additional component for selected patients rather than a substitute for systemic treatment.
Can individual metastases be irradiated?
Radiation can be used to:
- relieve painful bone metastases;
- treat threatening spinal lesions;
- control selected symptomatic masses;
- or, in research-oriented oligometastatic strategies, target limited metastatic deposits.
The role of metastasis-directed treatment as a routine survival-improving strategy in established M1 disease remains more selective than standard systemic treatment.
What is metastatic castration-resistant prostate cancer?
Metastatic castration-resistant prostate cancer, or mCRPC, means:
- metastatic disease is present;
- testosterone is suppressed to a castrate level;
- yet the cancer is still progressing.
Progression may be:
- PSA-based;
- radiographic;
- or clinical.
Does ADT stop when the cancer becomes castration-resistant?
Usually no.
Androgen suppression is generally continued while another effective treatment is added or sequenced.
What treatments are used in mCRPC?
Depending on previous therapy, symptoms, genetics and tumor characteristics, options can include:
- androgen-receptor pathway inhibitors;
- docetaxel;
- cabazitaxel after appropriate prior therapy;
- PARP-inhibitor strategies for tumors with qualifying DNA-repair alterations;
- PSMA-targeted radioligand treatment for selected PSMA-positive disease;
- radium-223 for selected symptomatic bone-predominant disease without visceral metastases;
- immunotherapy in selected molecular or clinical settings;
- and palliative radiation.
Why can BRCA testing matter?
Some metastatic prostate cancers contain inherited or acquired defects in homologous-recombination DNA-repair genes.
Examples include:
- BRCA2;
- BRCA1;
- ATM;
- and other pathway genes.
These findings can influence eligibility for targeted treatment.
An inherited pathogenic variant can also have implications for biological relatives.
See BRCA1, BRCA2 and Prostate Cancer for the inherited-risk context.
What is PSMA-targeted radioligand therapy?
This approach attaches a therapeutic radioactive isotope to a molecule that binds PSMA on prostate-cancer cells.
The aim is to deliver radiation preferentially to PSMA-expressing tumor sites throughout the body.
Patient selection depends on:
- PSMA imaging;
- previous treatments;
- blood counts;
- organ function;
- and the specific regulatory indication.
What is radium-223?
Radium-223 is an alpha-emitting radiopharmaceutical that behaves similarly to calcium and localizes to areas of active bone turnover.
It can be used in selected men with:
- castration-resistant disease;
- symptomatic bone metastases;
- and no known visceral metastases.
It is not a general treatment for liver or lung metastases.
How are painful bone metastases treated?
Treatment can include:
- systemic prostate-cancer therapy;
- external-beam radiation to painful sites;
- analgesic medication;
- orthopedic stabilization when fracture risk is high;
- treatment of spinal cord compression;
- and selected bone-targeted therapies.
Why does bone health need attention during ADT?
Long-term androgen deprivation can accelerate bone loss even in patients without bone metastases.
Bone-health assessment may therefore include:
- fracture-risk evaluation;
- DEXA scanning when appropriate;
- adequate dietary calcium;
- vitamin D assessment or supplementation when indicated;
- weight-bearing exercise when safe;
- and antiresorptive treatment for selected patients at significant fracture risk.
What is the goal of treatment in metastatic disease?
Treatment goals commonly include:
- prolonging survival;
- delaying progression;
- preventing skeletal complications;
- controlling pain and other symptoms;
- preserving mobility;
- maintaining urinary function;
- and protecting quality of life.
Distant metastatic prostate cancer is generally managed as a systemic disease rather than assumed to be curable through treatment of the prostate alone.
Treatment sequence matters. A drug that is appropriate before chemotherapy may not be the best choice after prior exposure to the same pathway. Modern metastatic care therefore tracks not only stage but also every prior systemic therapy, treatment response, genomic result and clinically important metastatic site.
→Metastatic Prostate Cancer Classification at a Glance
| Classification | Meaning | Common clinical implication |
|---|---|---|
| N1 M0 | Regional pelvic lymph-node involvement without distant metastasis. | Advanced regional disease, but not distant metastatic prostate cancer. |
| M1a | Non-regional lymph-node metastasis. | Systemic metastatic-disease framework. |
| M1b | Bone metastasis. | Systemic treatment plus attention to pain, fracture risk, cord compression and bone health. |
| M1c | Other distant metastatic site, including visceral disease. | Systemic therapy selected according to disease biology, burden and prior treatment. |
| De novo metastatic | Metastases are present when prostate cancer is first diagnosed. | Initial treatment commonly starts with intensified systemic therapy. |
| Metachronous metastatic | Metastases appear after an earlier localized diagnosis or treatment. | Previous treatment history strongly affects the next therapy. |
| mHSPC / mCSPC | Metastatic cancer still responsive to androgen suppression. | ADT plus guideline-supported treatment intensification for suitable patients. |
| mCRPC | Metastatic cancer progressing despite castrate testosterone levels. | Continue androgen suppression and select additional systemic therapy according to prior treatment and biomarkers. |
?Common Questions About Metastatic Prostate Cancer
| Question | Practical answer |
|---|---|
| What is metastatic prostate cancer? | Prostate cancer that has spread to a distant site outside the regional pelvic disease field. In TNM staging it is M1. |
| Is metastatic prostate cancer the same as advanced prostate cancer? | Metastatic disease is advanced, but advanced prostate cancer can also include nonmetastatic locally advanced or recurrent disease. |
| Where does prostate cancer most commonly spread? | Bone and lymph nodes are major metastatic sites; visceral organs such as liver or lung can also be involved. |
| What is M1a prostate cancer? | Metastasis to non-regional lymph nodes. |
| What is M1b prostate cancer? | Bone metastasis. |
| What is M1c prostate cancer? | Metastasis to another distant site or organ. |
| Are pelvic lymph nodes M1a? | Not if they are regional pelvic nodes. Regional nodal involvement is N1; non-regional nodes are M1a. |
| Is prostate cancer in bone the same as bone cancer? | No. It remains prostate cancer because the metastatic cells originated in the prostate. |
| Why does prostate cancer spread to bone? | Prostate-cancer cells can interact favorably with the marrow and bone microenvironment, allowing metastatic growth. |
| Are prostate bone metastases osteoblastic? | They commonly stimulate osteoblastic or sclerotic bone formation, although metastatic bone remodeling can involve both bone formation and breakdown. |
| Does bone metastasis always hurt? | No. Some skeletal metastases are asymptomatic and detected only on imaging. |
| Does back pain mean prostate cancer has spread? | No. Back pain is common and nonspecific. |
| When is back pain urgent? | Urgent assessment is needed when new or worsening back pain is accompanied by leg weakness, numbness, walking difficulty or new bladder/bowel dysfunction. |
| Can prostate cancer spread to the liver? | Yes. Liver involvement is a form of M1c visceral metastasis. |
| Can prostate cancer spread to the lungs? | Yes. Lung metastases can occur and are classified within M1c. |
| Can prostate cancer spread to the brain? | Yes, but brain metastasis is much less common than bone or nodal disease. |
| Can metastatic prostate cancer have no symptoms? | Yes. Metastases may be detected on staging imaging before symptoms occur. |
| Can PSA prove that cancer is metastatic? | No. PSA can indicate disease activity or risk but cannot identify the presence or location of metastases. |
| What scan is used for metastatic prostate cancer? | PSMA PET/CT is increasingly important. CT, MRI and bone scan also remain useful depending on the clinical situation. |
| Does every PSMA-positive lesion mean prostate cancer? | No. PSMA uptake must be interpreted with anatomical and clinical context. |
| What is de novo metastatic prostate cancer? | Metastatic disease present when prostate cancer is first diagnosed. |
| What is metachronous metastatic disease? | Metastases that develop after an earlier diagnosis or treatment of nonmetastatic prostate cancer. |
| What is metastatic hormone-sensitive prostate cancer? | M1 cancer that still responds to lowering or blocking androgen signaling. |
| Is ADT alone still standard treatment? | For most suitable newly diagnosed M1 patients, modern guidelines recommend ADT plus an additional effective systemic treatment rather than ADT alone. |
| What medicines are added to ADT? | Depending on the patient and local approvals, options can include abiraterone, apalutamide, enzalutamide, darolutamide and selected chemotherapy-based combinations. |
| What is triplet therapy? | A combination of ADT, docetaxel and an additional androgen-receptor pathway treatment in selected patients. |
| Can the prostate still be irradiated if cancer has already spread? | Yes. Prostate radiotherapy is recommended in selected men with newly diagnosed low-volume M1 disease as part of systemic treatment. |
| Does prostate radiation cure all metastatic disease? | No. M1 disease requires systemic therapy because cancer cells exist outside the local radiation field. |
| What is metastatic castration-resistant prostate cancer? | M1 prostate cancer that progresses despite testosterone being maintained at castrate levels. |
| Does ADT stop in mCRPC? | Usually not. Androgen suppression is generally continued while additional systemic treatment is selected. |
| Can BRCA mutations affect treatment? | Yes. Selected DNA-repair alterations can make some metastatic cancers eligible for PARP-inhibitor strategies. |
| What is PSMA radioligand therapy? | A systemic treatment that uses a radioactive molecule targeted to PSMA-expressing prostate-cancer cells in selected patients. |
| What is radium-223 used for? | It can be used in selected men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. |
| Can radiation help bone pain? | Yes. External-beam radiation can provide effective relief for many painful metastatic bone lesions. |
| Why is bone health important during treatment? | Both metastatic bone disease and long-term androgen deprivation can increase skeletal risk. |
| Can metastatic prostate cancer be cured? | Distant metastatic disease is generally treated as a systemic condition requiring long-term cancer control rather than assumed curable with local treatment alone. |
| Can metastatic prostate cancer be controlled for years? | Yes. Disease course varies widely, and modern systemic treatments can produce prolonged control in many patients. |
| What determines prognosis? | Important factors include metastatic sites and volume, Grade Group, PSA behavior, hormone sensitivity, genomic biology, symptoms, health status and response to treatment. |
ΣKey Clinical Takeaways
- Metastatic prostate cancer means prostate cancer has spread to a distant site.
- Distant metastatic disease is classified as M1.
- M1a means non-regional lymph-node metastasis.
- M1b means bone metastasis.
- M1c means another distant metastatic site or organ.
- Regional pelvic lymph nodes are N1 rather than M1a.
- A metastasis retains the identity of the original prostate cancer.
- Prostate cancer in bone is not primary bone cancer.
- Prostate cancer can spread through lymphatic and blood-vessel pathways.
- Bone is a major metastatic site in prostate cancer.
- Spine, pelvis and ribs are common skeletal locations.
- Prostate-cancer bone metastases often have an osteoblastic or sclerotic imaging pattern.
- Bone metastases can still weaken bone despite increased bone formation on imaging.
- Distant lymph-node disease is M1a.
- Liver and lung metastases fall within M1c.
- Brain metastases can occur but are much less common than bone or nodal disease.
- A patient can have bone, nodal and visceral metastases simultaneously.
- De novo metastatic disease is present at the initial prostate-cancer diagnosis.
- Metachronous metastases appear later after an earlier nonmetastatic diagnosis or treatment.
- Metastatic burden can influence treatment selection.
- Low-volume and high-volume classifications used in trials are not interchangeable with TNM categories.
- Metastatic disease may be completely asymptomatic.
- PSA alone cannot prove the presence or location of metastasis.
- PSMA PET/CT can detect nodal, skeletal and visceral prostate-cancer deposits.
- PSMA PET/CT is generally more sensitive than conventional staging for many small nodal and bone metastases.
- A PSMA-positive lesion is not automatically malignant and still requires expert interpretation.
- CT provides structural staging information.
- Bone scan detects increased skeletal turnover rather than prostate-cancer cells directly.
- MRI is especially useful for spinal, marrow and local soft-tissue assessment.
- New back pain with leg weakness, numbness, walking difficulty or bladder/bowel dysfunction can signal cord or cauda-equina compression and needs urgent assessment.
- Metastatic prostate cancer is also classified by hormone response.
- Metastatic hormone-sensitive prostate cancer still responds to androgen suppression.
- ADT is the systemic treatment foundation for hormone-sensitive metastatic disease.
- For suitable M1 patients, ADT monotherapy is generally no longer preferred when combination therapy can be given.
- Androgen-receptor pathway treatment can be added to ADT.
- Selected fit patients can receive docetaxel-containing intensified treatment.
- Triplet therapy combines ADT, chemotherapy and an additional androgen-pathway agent in selected settings.
- Prostate radiation can improve outcomes in selected patients with newly diagnosed low-volume metastatic disease.
- Local prostate radiation does not replace systemic treatment once M1 disease exists.
- Metastatic castration-resistant prostate cancer progresses despite castrate testosterone levels.
- ADT is generally continued when metastatic disease becomes castration-resistant.
- mCRPC treatment can include androgen-pathway agents, chemotherapy, targeted therapy, radiopharmaceuticals and symptom-directed radiation.
- BRCA and other DNA-repair alterations can influence treatment selection.
- PSMA-targeted radioligand therapy can be used in appropriately selected PSMA-positive disease.
- Radium-223 is a specialized option for selected symptomatic bone-metastatic castration-resistant disease without visceral metastasis.
- Bone health requires attention because both metastases and androgen deprivation affect the skeleton.
- Distant metastatic prostate cancer is generally managed as a systemic disease requiring long-term control.
- Prognosis cannot be determined from the word “metastatic” alone.
- Site, volume, hormone sensitivity, Grade Group, genomics, treatment history and treatment response all matter.
Clinical bottom line: metastatic prostate cancer is M1 disease—prostate cancer that has established distant deposits outside the regional pelvic field. The pattern of spread matters: M1a identifies non-regional lymph nodes, M1b identifies bone and M1c identifies other distant sites. Bone and lymph nodes are major metastatic destinations, but symptoms alone cannot establish whether spread has occurred. Modern staging increasingly uses PSMA PET/CT together with other imaging when appropriate. Treatment then depends not only on where the cancer has spread but also on whether it remains hormone-sensitive, how much metastatic disease is present, what treatments have already been used and whether actionable molecular alterations are present. For most suitable men with newly diagnosed metastatic hormone-sensitive disease, modern care uses intensified ADT-based combination therapy rather than ADT alone.
Medical disclaimer: This article provides general medical education about metastatic prostate cancer. Treatment must be individualized according to metastatic sites and burden, symptoms, PSA, Grade Group, hormone sensitivity, prior therapy, genomic findings, kidney and liver function, bone health, overall fitness and personal treatment priorities. New neurological symptoms, suspected spinal cord compression or uncontrolled severe pain require prompt medical evaluation.
For the disease states that can occur before M1 spread, see Localized Prostate Cancer, Advanced Prostate Cancer and Prostate Cancer Stages. For the pathology biology that modifies metastatic risk and prognosis, review What Is the Gleason Score? and Gleason Score vs Grade Group. For the diagnostic pathway that establishes prostate cancer before staging, see How Prostate Cancer Is Diagnosed and Prostate MRI. For PSA interpretation during progression or recurrence, review PSA Testing and PSA Doubling Time. For inherited and tumor DNA-repair biology relevant to selected metastatic treatments, see BRCA1, BRCA2 and Prostate Cancer. For the broader disease framework, return to the Prostate Cancer hub. The next guide explains prostate cancer bone metastases, including skeletal symptoms, imaging, fracture risk, spinal cord compression and treatment of bone complications.
Evidence Sources
- European Association of Urology — Prostate Cancer Classification and Staging Systems: TNM classification, M1a distant lymph-node disease, M1b bone metastasis and M1c other distant metastasis.
- European Association of Urology — Prostate Cancer Treatment: current metastatic hormone-sensitive and castration-resistant treatment recommendations, ADT intensification, docetaxel-based combinations, prostate radiotherapy in low-volume M1 disease, genomic testing and supportive care.
- European Association of Urology — Diagnostic Evaluation: PSMA PET/CT, conventional imaging, bone staging and assessment of metastatic disease.
- EAU Patient Information — Advanced Metastatic Prostate Cancer: metastatic disease, systemic treatment, chemotherapy, targeted therapy, radiopharmaceutical treatment and supportive care.
- National Cancer Institute — Hormone Therapy for Prostate Cancer: androgen deprivation, metastatic castration-sensitive disease, treatment intensification and castration-resistant prostate cancer.
- National Cancer Institute — Prostate Cancer Treatment PDQ: treatment of advanced, recurrent, hormone-sensitive and hormone-resistant prostate cancer.
- National Cancer Institute — Prostate Cancer Treatment, Health Professional Version: stage-specific systemic treatment, metastatic disease and recurrent prostate cancer.
- National Cancer Institute — Advances in Prostate Cancer Research: newer hormone treatments, castration-resistant disease, targeted therapies and ongoing treatment research.
